US 10,174,113 B2
Treatment of PD-L1-Negative Melanoma Using an Anti-PD-1 Antibody and an Anti-CTLA-4 AntibodyGeneral
US 10,174,113 B2
Treatment of PD-L1-Negative Melanoma Using an Anti-PD-1 Antibody and an Anti-CTLA-4 Antibody
Tech Center:
1600 Biotechnology and Organic Chemistry
Examiner:
Ilia I Ouspenski
Art Unit:
1644 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology
Inventors:
Arvin YANG
Assignee:
Priority:
04/28/16
Filed:
04/28/16
Granted:
01/08/19
Expiration:
11/26/35
Abstract
The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1-negative melanoma and (ii) administering to the patient a combination of an anti-PD-1 antibody or an antigen-binding portion thereof and an anti-CTLA-4 antibody or an antigen-binding portion thereof. The methods of the invention can extend progression-free survival for over 8 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.
Cooperative Patent Classification (CPC)
A61A61K2039/545A61P35/00A61KG01N2333/70503G01NC07K16/2818C07K